Cargando…
Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review
BACKGROUND: Despite genetic polymorphism in response to platinum/5-Fu chemotherapy in gastric cancer (GC) has been studied, data reported so far are conflicting and critical consideration is needed before translation to the treatment of GC. METHODS: We performed a meta-analysis by using 20 eligible...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3524027/ https://www.ncbi.nlm.nih.gov/pubmed/23020798 http://dx.doi.org/10.1186/1471-230X-12-137 |
_version_ | 1782253258542153728 |
---|---|
author | Wang, Zhen Chen, Jun-qiang Liu, Jin-lu Qin, Xin-gan Huang, Yuan |
author_facet | Wang, Zhen Chen, Jun-qiang Liu, Jin-lu Qin, Xin-gan Huang, Yuan |
author_sort | Wang, Zhen |
collection | PubMed |
description | BACKGROUND: Despite genetic polymorphism in response to platinum/5-Fu chemotherapy in gastric cancer (GC) has been studied, data reported so far are conflicting and critical consideration is needed before translation to the treatment of GC. METHODS: We performed a meta-analysis by using 20 eligible studies to examine polymorphisms of ERCC1, GSTs, TS and MTHFR in predicting clinical outcomes (response rate, overall survival and toxicity) of GC patients treated with platinum/5-Fu-based chemotherapy. The association was measured using random/fixed effect odds ratios (ORs) or hazard ratios (HRs) combined with their 95% confidence intervals (CIs) according to the studies’ heterogeneity. Statistical analysis was performed with the software STATA 9.0 package. RESULTS: No significant association was found between response rate and genetic polymorphism in TS, MTHFR, ERCC1, GSTM1 and GSTP1. However, response rate was higher in GSTT1 (+) genotype compared with GSTT1 (−) genotype (T-/T+: OR=0.67, 95% CI: 0.47–0.97). With regard to long term outcomes, we could observe a significant longer overall survival in TS 3R/3R [(2R2R+2R3R)/3R3R: HR=1.29, 95% CI: 1.02–1.64] and GSTP1 GG/GA [(GG+AG)/AA: HR=0.51, 95% CI: (0.39, 0.67)] genotypes. In addition, significant association was demonstrated between toxicity and genetic polymorphism in TS, MTHFR and GSTP1 in included studies. CONCLUSION: Polymorphisms of ERCC1, GSTs, TS and MTHFR were closely associated with clinical outcomes of GC patients treated with platinum/5-Fu-based chemotherapy. Studies with large sample size using the method of multi-variant analyses may help us to give more persuasive data on the putative association in future. |
format | Online Article Text |
id | pubmed-3524027 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35240272012-12-18 Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review Wang, Zhen Chen, Jun-qiang Liu, Jin-lu Qin, Xin-gan Huang, Yuan BMC Gastroenterol Research Article BACKGROUND: Despite genetic polymorphism in response to platinum/5-Fu chemotherapy in gastric cancer (GC) has been studied, data reported so far are conflicting and critical consideration is needed before translation to the treatment of GC. METHODS: We performed a meta-analysis by using 20 eligible studies to examine polymorphisms of ERCC1, GSTs, TS and MTHFR in predicting clinical outcomes (response rate, overall survival and toxicity) of GC patients treated with platinum/5-Fu-based chemotherapy. The association was measured using random/fixed effect odds ratios (ORs) or hazard ratios (HRs) combined with their 95% confidence intervals (CIs) according to the studies’ heterogeneity. Statistical analysis was performed with the software STATA 9.0 package. RESULTS: No significant association was found between response rate and genetic polymorphism in TS, MTHFR, ERCC1, GSTM1 and GSTP1. However, response rate was higher in GSTT1 (+) genotype compared with GSTT1 (−) genotype (T-/T+: OR=0.67, 95% CI: 0.47–0.97). With regard to long term outcomes, we could observe a significant longer overall survival in TS 3R/3R [(2R2R+2R3R)/3R3R: HR=1.29, 95% CI: 1.02–1.64] and GSTP1 GG/GA [(GG+AG)/AA: HR=0.51, 95% CI: (0.39, 0.67)] genotypes. In addition, significant association was demonstrated between toxicity and genetic polymorphism in TS, MTHFR and GSTP1 in included studies. CONCLUSION: Polymorphisms of ERCC1, GSTs, TS and MTHFR were closely associated with clinical outcomes of GC patients treated with platinum/5-Fu-based chemotherapy. Studies with large sample size using the method of multi-variant analyses may help us to give more persuasive data on the putative association in future. BioMed Central 2012-09-29 /pmc/articles/PMC3524027/ /pubmed/23020798 http://dx.doi.org/10.1186/1471-230X-12-137 Text en Copyright ©2012 Wang; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Wang, Zhen Chen, Jun-qiang Liu, Jin-lu Qin, Xin-gan Huang, Yuan Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review |
title | Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review |
title_full | Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review |
title_fullStr | Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review |
title_full_unstemmed | Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review |
title_short | Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review |
title_sort | polymorphisms in ercc1, gsts, ts and mthfr predict clinical outcomes of gastric cancer patients treated with platinum/5-fu-based chemotherapy: a systematic review |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3524027/ https://www.ncbi.nlm.nih.gov/pubmed/23020798 http://dx.doi.org/10.1186/1471-230X-12-137 |
work_keys_str_mv | AT wangzhen polymorphismsinercc1gststsandmthfrpredictclinicaloutcomesofgastriccancerpatientstreatedwithplatinum5fubasedchemotherapyasystematicreview AT chenjunqiang polymorphismsinercc1gststsandmthfrpredictclinicaloutcomesofgastriccancerpatientstreatedwithplatinum5fubasedchemotherapyasystematicreview AT liujinlu polymorphismsinercc1gststsandmthfrpredictclinicaloutcomesofgastriccancerpatientstreatedwithplatinum5fubasedchemotherapyasystematicreview AT qinxingan polymorphismsinercc1gststsandmthfrpredictclinicaloutcomesofgastriccancerpatientstreatedwithplatinum5fubasedchemotherapyasystematicreview AT huangyuan polymorphismsinercc1gststsandmthfrpredictclinicaloutcomesofgastriccancerpatientstreatedwithplatinum5fubasedchemotherapyasystematicreview |